医学
不利影响
瘢痕疙瘩
皮肤病科
统计显著性
内科学
维生素D与神经学
交叉研究
肉毒毒素
维生素
临床试验
外科
累积剂量
胰岛素
恶化
队列
失明
非那雄胺
维拉帕米
作者
Camila Sánchez Cruz,Angelo Magallanes Bajana,William Matheus de Araujo,Christopher Romero Rios,Malaz El Zubair Mohamed Khalil,Jose Medina,Karla Perozo,Alexa Bentley,E. Calderon Martinez,Candela Romano
出处
期刊:
[Figshare (United Kingdom)]
日期:2026-03-20
标识
DOI:10.6084/m9.figshare.31820113
摘要
Keloids are pathological scars causing pain, pruritus, and emotional distress. While common treatments exist, emerging options such as insulin and botulinum toxin A (BTX-A) are underrepresented in comparative analyses. This network meta-analysis (NMA) aimed to evaluate the efficacy and safety profiles of various intralesional therapies for keloid scars. A PRISMA-guided search across seven databases was conducted on July 2025 and preregistered on PROSPERO (CRD420251088758). Included studies were randomized, non-randomized, and crossover trials of intralesional therapies. Pairwise and NMA were conducted for efficacy (keloid size/volume reduction), recurrence, and safety (adverse effects). Treatment rankings were based on surface under the cumulative ranking curve (SUCRA) scores. Statistical significance was set at (p < 0.05). From 51 studies (3234 participants, 23 interventions), 5-fluorouracil (5-FU) + corticoids significantly improved keloid reduction compared to corticoids alone (RR = 1.59; 95% CI: 1.31–1.92; p < 0.01), with 5-FU + corticoids + YAG:Laser (RR = 2.73; 95% CI: 1.36–5.48; p < 0.01) showing an even greater effect. SUCRA values indicated that 5-FU + corticoids + YAG:Laser (0.95), vitamin D + platelet rich plasma (0.83), and 5-FU + corticoids (0.78) had the highest probability of effectiveness. For recurrence, no significant differences were found across interventions, suggesting insufficient evidence. Regarding adverse effects, a significant risk reduction was found for BTX-A (RR = 0.29; 95% CI: 0.09–0.95; p = 0.04) and Verapamil (RR = 0.35; 95% CI: 0.14–0.84; p = 0.01) compared to corticoids; others showed no significant effects. This NMA provides a comparative overview, indicating that combination therapies, most notably 5-FU + corticoids + YAG:Laser, offer the greatest benefit. While data for novel agents (insulin and BTX-A) suggest potential, further research with standardized methodologies and longer-term follow-up is crucial to define optimal treatment algorithms.
科研通智能强力驱动
Strongly Powered by AbleSci AI